Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -0.88%77 Price-to-Owner-Earnings is 19.26 as of Aug. 04, 2026, which is 57% below its 10-year median of 45.07. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 316 Medical Devices & Instruments companies, Coloplast AS ranks better than 66.77% on this metric.
As of today (2026-08-04), Coloplast AS's share price is $6.74.
Coloplast AS's Owner Earnings per Share (TTM) ended in Mar. 2026 was $0.35. It's Price-to-Owner-Earnings for today is 19.26.
The historical rank and industry rank for Coloplast AS's Price-to-Owner-Earnings or its related term are showing as below:
CLPBY'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.4 Med: 45.07 Max: 61.23
Current: 18.96
During the past 13 years, the highest Price-to-Owner-Earnings of Coloplast AS was 61.23. The lowest was 16.40. And the median was 45.07.
CLPBY's Price-to-Owner-Earnings is ranked better than 66.77% of 316
companies
in the Medical Devices & Instruments industry
Industry Median: 27.075
vs CLPBY: 18.96
Coloplast AS Price-to-Owner-Earnings Related Terms
Coloplast AS Price-to-Owner-Earnings Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Price-to-Owner-Earnings Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Price-to-Owner-Earnings vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Coloplast AS's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Owner-Earnings of 19.26 mean?
Coloplast AS (CLPBY) has a Price-to-Owner-Earnings of 19.26 as of Aug. 04, 2026. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Coloplast AS and its competitors. This is 57% below median its historical median of 45.07. Over the past decade, Coloplast AS's Price-to-Owner-Earnings has ranged from 16.40 to 61.23. According to the industry distribution chart, Coloplast AS ranks #105 out of 316 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Coloplast AS's Price-to-Owner-Earnings too high?
Coloplast AS's current Price-to-Owner-Earnings of 19.26 is 57% below median its 10-year median of 45.07. Over the past 10 years, this metric has ranged from a low of 16.40 to a high of 61.23. The Medical Devices & Instruments industry median Price-to-Owner-Earnings is 27.08. Coloplast AS's value of 19.26 is 28.9% below this industry median. Based on the distribution chart, Coloplast AS ranks #105 out of 316 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Price-to-Owner-Earnings compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #105 out of 316 companies for Price-to-Owner-Earnings. This puts Coloplast AS in the upper half of its industry. The industry median Price-to-Owner-Earnings is 27.08. Coloplast AS's value of 19.26 is 28.9% below this benchmark. Historically, Coloplast AS's own Price-to-Owner-Earnings has ranged from 16.40 to 61.23 over the past decade. While the company's 10-year median is 45.07 vs. the industry median of 27.08, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Owner-Earnings for a Medical Devices & Instruments company?
The median Price-to-Owner-Earnings among Medical Devices & Instruments companies is 27.08, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Owner-Earnings significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Owner-Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Price-to-Owner-Earnings of 19.26 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Owner-Earnings mean?
A high Price-to-Owner-Earnings can signal that a stock is expensive relative to its fundamentals. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Owner-Earnings is 27.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Price-to-Owner-Earnings is 19.26, which is 57% below median its own 10-year median of 45.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.74 — trading 48.4% below its estimated fair value. The current Price-to-Owner-Earnings is 19.26, which is 57% below median its 10-year median of 45.07 and 28.9% below the Medical Devices & Instruments industry median of 27.08. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Owner-Earnings calculated?
Price-to-Owner-Earnings is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Price-to-Owner-Earnings is 19.26 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.74 is trading 48.4% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Price-to-Owner-Earnings: 19.26 (57% below median its 10-year median of 45.07)
GF Value™: $13.05 vs. price of $6.74 (48.4% below fair value)
Industry Position: 28.9% below the Medical Devices & Instruments median (#105 of 316)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
